In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

The first of three phase 3 trials of Neumora Therapeutics' novel antidepressant navacaprant has ended in failure, wreaking ...

Hutchmed has agreed to divest its share of a Chinese joint venture company through a pair of deals that will give it a cash ...